Efficacy of administering remimazolam at anesthetic management for awake craniotomy

JRCT ID: jRCT1041200094

Registered date:28/01/2021

Basic Information

• Recruitment status: Recruiting
• Health condition(s) or Problem(s) studied: Brain tumor
• Date of first enrollment: 05/02/2021
• Target sample size: 58
• Study type: Interventional
• Intervention(s): Setting of remimazolam administration group and propofol administration group

Outcome(s)

• Primary Outcome: Time (second) needed to awake before awake phase.

Key inclusion & exclusion criteria

• Age minimum: >= 15age old
• Age maximum: <= 70age old
• Gender: Both
• Include criteria: Patients who undergo elective awake craniotomy

Exclude criteria

1)Patients who do not agree.
2)have a liver disfunction(Child-pugh classification B or higher).
3)have an allergy for the ropivacaine and other anesthetics drugs.
4)have an obvious hemostatic dysfunction(Platelet count of 80000 or less,PT-INR of 1.5 or more,APTT of 40 seconds or more).
5)have a severe respiratory disorder(%VC<60%,orFEV1%<50%).
6)have a primary closed angle glaucoma
7)have a heart failure (ejection fraction of 45% or less on echocardiography, presence of severe valvular disease, and past history of coronary artery disease).
8)patient who can not be in candidate at this study decided by the doctor

Related Information

• Primary Sponsor: Nishiwaki Kimitoshi